• Innate Pharma Q1 2026 update highlighted interim results from MATISSE Phase 2, already presented at AACR Annual Meeting 2026, testing IPH5201 with durvalumab and chemotherapy before surgery in early-stage non-small cell lung cancer.
• Study signaled encouraging tumor clearance outcomes, with performance appearing stronger in patients with PD-L1-positive disease, supporting continued enrollment focused on that population.
• Innate also plans to start lacutamab confirmatory Phase 3 TELLOMAK-3 trial in H2 2026 in cutaneous T-cell lymphoma, positioning program for potential accelerated approval pathway once trial is underway.
• Separate Phase 3 PACIFIC-9 readout for monalizumab in unresectable Stage III NSCLC remains expected in H2 2026, setting up a major catalyst for partnered asset.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innate Pharma SA published the original content used to generate this news brief via Business Wire (Ref. ID: 20260512637251) on May 13, 2026, and is solely responsible for the information contained therein.